H.C. Wainwright raised the firm’s price target on Celcuity (CELC) to $66 from $50 and keeps a Buy rating on the shares following the Q2 report. The firm expects a gedatolisib new drug application submission and clinical data updates before year end.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELC:
- Celcuity’s Geda Triplet Therapy Shows Promising Phase III Results, Justifying Buy Rating
- Celcuity’s Strong Prospects: Buy Rating Affirmed Amidst Positive Drug Developments and Robust Financial Position
- Celcuity Inc. Reports Promising Q2 2025 Results
- Celcuity reports Q2 EPS (93c), consensus (85c)
- Celcuity’s Promising Clinical Trial Results and Strong Buy Recommendation by Andrew Berens